Uncertainty in patent rights undermines the investment needed to turn scientific breakthroughs into commercial products—but accepting that uncertainty is a choice. In this episode of IPWatchdog Unleashed, Judge Pauline Newman draws on her experience in industry and the policy discussions that helped shape the Federal Circuit to connect today’s life sciences challenges with the conditions that drove an earlier era of patent reform. She explains why predictable, reliable patent protection matters to research investment, commercialization, and the ability to recover the costs of failed research as well as successful discoveries. Her message to IP counsel, industry leaders, and policymakers is direct: addressing the weaknesses of the patent system requires looking beyond how to navigate existing law and engaging in the work of changing it.
Today, the U.S. Supreme Court issued an order list including denials of a pair of petitions for writ of certiorari challenging subject matter eligibility analyses under 35 U.S.C. § 101 by the U.S. Court of Appeals for the Federal Circuit. These denials continue the Court’s trend of ignoring loud alarms raised regarding the Federal Circuit’s application of the Court’s two-step patentability test under Alice Corp. v. CLS Bank International, especially the intra-circuit development of conflicting standards for analyzing subject matter eligibility of computer-related inventions.
The U.S. Court of Appeals for the Federal Circuit (CAFC) issued a precedential decision on Friday, November 13, in In re Netlist, Inc., affirming the Patent Trial and Appeal Board’s (PTAB) determination that all challenged claims of two Netlist memory module patents are unpatentable as obvious. Circuit Judge Dyk wrote for the court, joined by Circuit Judges Linn and Chen, and rejected Netlist’s argument that the PTAB erred in finding a motivation to combine since the combination would be inoperable for the intended purpose of the primary reference and would lose that reference’s key benefits.
Attribution uncertainty should be treated as a distinct source of intellectual property risk and priced into the valuation of AI-assisted inventions. When an invention emerges from a workflow in which human contributions were not documented, an inventorship error can threaten patent validity and, in some circumstances, may not be correctable. A patent is worth less if its owner cannot reliably establish who invented the claimed subject matter, which matters to buyers, licensees, lenders, insurers, and technology-transfer offices alike.
This week on IPWatchdog Unleashed, we discuss how a credible trial preparation supports settlement leverage. From the in-house vantage point, a litigation team’s ability to articulate a persuasive case matters even when the preferred outcome is an early resolution. For patent owners, accused infringers, and the counsel advising them, this conversation highlights why audience awareness, technical clarity, and case development belong within the same strategy. The episode offers a substantive look at how experienced practitioners make those judgments—and how the choices made throughout a case shape both courtroom advocacy and the options available outside it.
This week on IPWatchdog Unleashed, we have a discussion about the IP risks associated with AI use and adoption, with Stephanie Curcio, Marlene Valderrama, Kendra Ervin and Rinat Shangeeta. The discussion reveals a consequential gap with how businesses are deploying AI. Many companies are moving faster to adopt AI than their governance, contracting and IP review processes can accommodate. For those responsible for protecting innovation and confidential information, the challenge is ensuring that enthusiasm for AI adoption does not obscure the consequences of how these tools are actually used.
Uncertainty in patent rights undermines the investment needed to turn scientific breakthroughs into commercial products—but accepting that uncertainty is a choice. In this episode of IPWatchdog Unleashed, Judge Pauline Newman draws on her experience in industry and the policy discussions that helped shape the Federal Circuit to connect today’s life sciences challenges with the conditions that drove an earlier era of patent reform. She explains why predictable, reliable patent protection matters to research investment, commercialization, and the ability to recover the costs of failed research as well as successful discoveries. Her message to IP counsel, industry leaders, and policymakers is direct: addressing the weaknesses of the patent system requires looking beyond how to navigate existing law and engaging in the work of changing it.
ArentFox Schiff LLP is seeking a senior patent agent or patent attorney with seven-plus years of experience to join its highly regarded patent prosecution team in our Boston, Chicago, Los Angeles, New York, San Francisco, Silicon Valley, or Washington, DC offices. A degree in Electrical Engineering is required.
Although U.S. Patent and Trademark Office (USPTO) Director John Squires just officially announced last week that former counsel to Judge Pauline Newman, Greg Dolin, will be the new Deputy General Counsel and Solicitor, following the appointment of John Duffy as General Counsel last month, nearly 14 months after Squires became Director on September 22, 2025, the agency continues to operate with significant leadership vacancies, temporary appointments, and weakened oversight.
This Week in Other Barks & Bites: the Federal Circuit rules that the inoperability of a prior art reference in combination with another does not extinguish the motivation to combine those references; the U.S. Trade Representative extends its Special 301 investigation into Vietnam’s IP practices through next February; and more.
The USPTO deserves some credit for recognizing that applicants may at times need an opportunity to explain technical improvements that examiners have failed to appreciate, but there is real risk associated with filing a SMED that should cause practitioners to pause rather than race forward without serious consideration. And despite some difference of opinion, we all agreed on an essential point: Filing a SMED should not be the first line of defense against an eligibility rejection; it should should be treated as a last resort. Filing a SMED requires serious consideration of the advantages, disadvantages, and alternatives. Examiner interviews, arguments grounded in the existing specification, appropriate claim amendments, and appeals all deserve careful consideration before ever adding sworn statements to the prosecution history. The question must be whether the declaration supplies something genuinely necessary to advance the case, and even then must be intentionally specific and narrow.
A patent’s economic value and the price it commands in a licensing negotiation can be very different things. The technology may deliver substantial commercial benefits, yet the amount a patent owner can capture depends on legal risk, enforcement costs, negotiating leverage, and each party’s business objectives. This week on IPWatchdog Unleashed, we ask how much a patent is really worth, and how to prove it at a negotiating table or in court. This conversation, which occurred as part of IPWatchdog’s 2026 Women’s IP Forum, examines how sophisticated licensors, licensees, counsel, and valuation professionals assess patent value in real-world transactions and disputes. The conversation explored royalty structures, comparable licenses, portfolio strength, litigation and validity risk, damages principles, standard-essential patent (SEP) licensing, and the practical factors that drive parties toward—or away from—a deal.
This week on IPWatchdog Unleashed, I speak with Nancy Braman. Recorded before a live audience at IPWatchdog’s 2026 Women’s IP Forum, our conversation explores how practitioners create opportunities, develop professional relationships, and build the skills necessary to succeed in patent law. From taking PLI patent bar review course before law school, to attending Franklin Pierce Law School, to spending more than three years writing and researching for IPWatchdog and now litigating high-stakes patent and intellectual property disputes for life sciences and technology companies. She has already had quite the journey, and I sense it is really just beginning.
This is the best way to stay informed. We send a daily roundup of our latest news, press releases, and events.
Get Email Updates